Arteriocyte Medical Systems

What Arteriocyte Medical Systems does

Arteriocyte Medical Systems, Inc. is a medical device company specializing in orthobiologic solutions for tissue healing and bone regeneration, operating as a wholly-owned subsidiary within the Isto Biologics integrated business group. Founded in 2007 and headquartered in Hopkinton, Massachusetts, the company develops and markets a portfolio of products spanning three categories: Autologous Therapies (the Magellan® Autologous Concentration System for creating Platelet Rich Plasma, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma, plus the Precise™ PRP system and Lightning™ Needle), Allografts (the Influx™ product family with variants including ProteiOS, Fibrant, SPARC, PLUS, Sponge, and OsseoGEN, derived from donor tissue), and Synthetics (InQu®, a biosynthetic bone graft with clinical evidence of outperforming ICBG fusion rates).

The company sells through a hybrid go-to-market model combining direct field sales representatives with a global distributor network, targeting orthopedic and spine surgeons, hospital administrators, and clinical researchers. Pricing follows a quote-based, consultative approach with 'Contact Your Rep' and 'Request a Quote' mechanisms on the Isto Biologics website. Since its founding, Arteriocyte has raised approximately $10.76M in disclosed funding, with the largest round a $10M investment led by DW Healthcare Partners in October 2007; the company is led by CEO Donald Brown and operates with 51-100 employees. No revenue figures, cap table, or recent funding activity have been publicly disclosed.

Name

Arteriocyte Medical Systems

Legal name

Arteriocyte Medical Systems, Inc.

Website

http://arteriocyte.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Arteriocyte Medical Systems is a medical device subsidiary of Isto Biologics that develops and markets orthobiologic products—including the market-leading Magellan autologous concentration system, Influx allograft line, and InQu synthetic bone grafts—for orthopedic and spine surgeons and hospital customers globally.

Ownership category

akta.pro rank

Product category

Orthobiologic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Orthobiologic medical devices
• Autologous therapy systems
• Bone graft products
• Platelet rich plasma
• Allograft tissue grafts

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels5 records

Core offering

Arteriocyte Medical Systems develops and sells orthobiologic medical devices and biologic products used by surgeons to support tissue healing and bone regeneration. Its portfolio includes the Magellan Autologous Concentration System (and kits) for creating Platelet Rich Plasma, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma; the Precise system for Leukocyte Rich/Poor PRP; the Lightning Needle autologous delivery device; the Influx allograft family (Fibrant, ProteiOS, SPARC, PLUS, Sponge, OsseoGEN) derived from donor tissue; and the InQu biosynthetic bone graft. These products serve orthopedic and spine surgeons across varying specialties in hospitals and surgical centers.

Product overview

Isto Biologics is a 100% biologics-focused company offering a unified portfolio of orthobiologic solutions across three product categories: Autologous Therapies, Allografts, and Synthetics. The Autologous Therapies portfolio includes the Magellan Autologous Concentration System (market-leading device for PRP and bone marrow concentrate), Precise (newest precision PRP system), and Lightning Needle. The Allografts portfolio centers on the Influx product family with multiple variants including Influx, Fibrant, ProteiOS, SPARC, PLUS, Sponge, and OsseoGEN. The Synthetics portfolio features InQu, a cell-friendly biosynthetic bone graft. These products are designed to help patients heal faster, serving surgeons across varying specialties with customizable options. Arteriocyte Medical Systems is one of the operating subsidiaries of Isto Biologics.

Differentiator

Problem solved

Functional benefit

Brands

• Magellan: Leading autologous concentration system for creating autologous therapies including Platelet Rich Plasma, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma
• Precise
• Lightning Needle
• Influx
• ProteiOS
• Influx Fibrant
• Influx SPARC
• Influx PLUS
• Influx Sponge
• OsseoGEN
• InQu

Products and services

• Magellan Autologous Concentration System Market-leading autologous concentration device used to create autologous therapies including Platelet Rich Plasma (PRP), Concentrated Bone Marrow Aspirate (cBMA), and Platelet Poor Plasma. Designed for surgeons and physicians across varying specialties performing autologous therapy procedures.
• Precise PRP System Newest addition to the Autologous Therapies portfolio providing options to create Leukocyte Rich and Leukocyte Poor PRP for precision targeting applications. Designed for surgeons needing targeted autologous therapy options.
• Lightning Needle Autologous therapy delivery device within the Autologous Therapies portfolio, designed for needle-based applications in biologic treatments.
• Influx Allograft Product Line Setting the standard for advanced allografts, the Influx product line is a differentiated bone grafting portfolio derived from donor tissue. Encompasses multiple variants (ProteiOS, Fibrant, SPARC, PLUS, Sponge) addressing various surgical and healing needs for orthopedic and spine surgeons.
• Influx Fibrant Breakthrough cortical fiber allograft within the Influx product family, designed for bone grafting procedures.
• Influx ProteiOS A blend of allograft-derived proteins, part of the Influx allograft product line for bone grafting applications.
• Influx SPARC Next generation allograft within the Influx product family, offering advanced grafting solutions for bone regeneration procedures.
• Influx PLUS Allograft product within the Influx family, designed for specific surgical applications.
• Influx Sponge Allograft product within the Influx family, designed for specific surgical applications.
• OsseoGEN

Quantifiable outcome

• InQu biosynthetic bone graft outperforms fusion rates of ICBG (autograft gold standard)

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Stryker: Stryker offers Vitoss, BIO4, and other bone graft substitutes through its Orthopedics and Spine segments, overlapping directly with Isto's Influx allograft and InQu synthetic bone graft portfolio across orthopedic and spine indications.
• DePuy Synthes (Johnson & Johnson): DePuy Synthes markets the HEALOS and CONDUIT bone graft substitutes and bundles them with trauma/spine hardware. It competes with Isto for hospital contract wins and surgeon adoption in trauma and spine fusion.
• Arthrex: Arthrex dominates orthopedic sports medicine with Autologous Conditioned Plasma (ACP) double-syringe system, a direct autologous PRP alternative to the Magellan system in sports medicine and orthopedic practices.
• Medtronic: Medtronic is the dominant spine and orthobiologics player through its Infuse Bone Graft (rhBMP-2) and broader Spine division. It competes directly with Isto's InQu and Influx lines for spine fusion and biologics formulary share at major hospital systems.

Direct peers

• LifeNet Health: LifeNet Health is a leading nonprofit allograft tissue processor with a comprehensive orthobiologics portfolio (e.g., OsteoSurge, ViviGen cellular bone matrix). It competes with Isto's Influx allograft family across spine, orthopedic, and dental indications.
• Bioventus: Bioventus offers a portfolio of orthobiologics including OSTEOAMP, Signafuse, and joint pain therapies (hyaluronic acid, PRP). It is a direct competitor in the autologous PRP (vs Magellan) and bone graft substitute (vs InQu) markets.
• MTF Biologics: MTF Biologics is one of the largest tissue banks offering allograft and cellular bone matrices (e.g., Trinity ELITE, Carticel) used in orthopedics and sports medicine. It directly competes with Isto's allograft and autologous portfolios in musculoskeletal procedures.
• SeaSpine: SeaSpine focuses exclusively on spine surgery with a biologics portfolio including OsteoStrand and Evo3D plus precision-machined allograft products. It is a niche direct competitor to Isto's Influx family in spine fusion and orthobiologics.
• NuVasive (now Globus Medical): NuVasive offers the Propensity DBM and other orthobiologics used in spine surgery. It is a direct competitor to Isto's Influx allograft family in spine fusion and is bundled with NuVasive's spine hardware offerings.

Emerging players

• EmCyte (now part of Royal Biologics): EmCyte/Genesis Systems makes the PureBMC and PurePRP autologous concentration systems, competing head-to-head with the Magellan system in orthobiologic and regenerative medicine practices.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCtu3EDFsT5_GdwOj8iOFg1g
• LinkedInlinkedin.com/company/arteriocyte
• Xx.com/Arteriocyte

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arteriocyte Medical Systems